Neurocrine Biosciences Tender Offer for Soleno Therapeutics Clears HSR Regulatory Hurdle
SLNO sits 79% above its 52-week low of $29.43 on light trading volume (0.4× avg).
Summary
Neurocrine Biosciences announced that the waiting period under the HSR Act for its tender offer to acquire Soleno Therapeutics has expired, satisfying a key regulatory condition for the acquisition.
Key Events · M&A and Partnerships · SLNO
-
HSR Act Waiting Period Expired
The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) applicable to the tender offer expired on April 27, 2026. This satisfies a key regulatory condition for the acquisition.
-
Tender Offer Progress
This amendment relates to the ongoing tender offer by Sigma Merger Sub, Inc., a subsidiary of Neurocrine Biosciences, to acquire all outstanding shares of Soleno Therapeutics for $53.00 per share in cash. The offer remains subject to other conditions.
Analysis · SLNO · Life Sciences
This amendment signals a significant step forward in the acquisition of Soleno Therapeutics by Neurocrine Biosciences. The expiration of the HSR Act waiting period satisfies a critical regulatory condition, substantially de-risking the tender offer. This increases the certainty that the acquisition will close as planned, providing clarity for Soleno shareholders regarding the $53.00 per share cash offer. Investors should monitor the remaining offer conditions and the tender period for further updates.
At the time of this filing, SLNO was trading at $52.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $29.43 to $90.32. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.